François Vigneault is co-founder and CEO at Shape Therapeutics. Prior to Shape, François co-founded AbVitro with Harvard Medical School Professor George Church, where he pioneered the development of high throughput immune single-cell sequencing. AbVitro was acquired by Juno Therapeutics, where François became VP of Research until its acquisition by Celgene and shortly after by Bristol Myers Squibb. Francois completed a postdoctoral Fellow in George Church’s lab at Harvard Medical School and holds a PhD in molecular biology, as well as a BA in microbiology. François also served for a decade as a Maritime Warfare Officer in the Canadian Navy.